Bone marrow mesenchymal stem cell transplantation alleviates myocardial injury due to systolic hypertension

doi:10.3969/j.issn.2095-4344.2016.50.010

Abstract

Abstract:

BACKGROUND: Mesenchymal stem cells can be used to treat a variety of injuries, but little is known about their effect on systolic hypertension.
OBJECTIVE: To study the therapeutic effect of bone marrow mesenchymal stem cells on systolic hypertension rats.
METHODS: Twenty-four rats were randomized equally into control, model and cell transplantation groups. A rat model of systolic hypertension was made by injection of vitamin K and warfarin sodium in the model and cell transplantation groups. Rats in the cell transplantation group were given injection of bone marrow mesenchymal stem cells into the left ventricle, while those in the other two groups given normal saline.
RESULTS AND CONCLUSION: Compared with the model group, bone marrow mesenchymal stem cells could reduce left ventricular mass index, increase cardiac tissue type I collagen volume fraction, collagen volume fraction and perivascular collagen volume fraction, but the ratio of end-diastolic volume/body weight did not change significantly. These findings indicate that bone marrow mesenchymal stem cell transplantation can reduce myocardial hypertrophy and cardiac fibrosis in systolic hypertension rats.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Systole, Hypertension, Tissue Engineering

CLC Number:

R394.2

Wang Yong, Zhang Ya-guang. Bone marrow mesenchymal stem cell transplantation alleviates myocardial injury due to systolic hypertension[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(50): 7518-7523.

Figures/Tables 2

References

[1] 吴寿岭,黄卫,戚长春,等.单纯收缩期高血压对老年人群心脑血管事件的影响[J].中华高血压杂志,2012,20(1): 67-71.

[2] Martin JN Jr. Severe systolic hypertension and the search for safer motherhood. Semin Perinatol. 2016; 40(2):119-123.

[3] 郭艺芳,刘琪.老年单纯收缩期高血压的治疗进展[J].心血管病学进展,2011,32(1):36-38.

[4] Modesti PA, Omboni S, Taddei S, et al. Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study. J Hypertens. 2016;34(3):576-587; discussion 587.

[5] 何杰.老年单纯收缩期高血压研究进展[J].心血管病学进展,2011,32(4):558-561.

[6] 涂维,陈秀龙.老年单纯收缩期高血压中西医治疗进展[J].中国老年保健医学,2013,11(5):69-71.

[7] 赵春美.老年单纯收缩期高血压治疗与靶器官保护探讨[J].实用中西医结合临床,2014,14(9):38-39.

[8] Kim NR, Kim HC. Prevalence and Trends of Isolated Systolic Hypertension among Korean Adults: the Korea National Health and Nutrition Examination Survey, 1998-2012. Korean Circ J. 2015;45(6):492-499.

[9] 范雯怡,武轶群,曹洋,等.降压0号治疗老年单纯收缩期高血压的疗效和安全性评价[J].现代预防医学,2012, 39(4): 1008-1010,1021.

[10] Khanabdali R, Saadat A, Fazilah M, et al. Promoting effect of small molecules in cardiomyogenic and neurogenic differentiation of rat bone marrow-derived mesenchymal stem cells. Drug Des Devel Ther. 2015; 10:81-91.

[11] Pollock K, Dahlenburg H, Nelson H, et al. Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models. Mol Ther. 2016;24(5):965-977.

[12] Parody R, Sureda A. Mesenchymal stromal cells for steroid-refractory acute GVHD. Lancet Haematol. 2016;3(1):e8-9.

[13] 朱光照.单纯收缩期高血压动物模型建立及其早期干预的实验研究[D].南昌:南昌大学,2008.

[14] 童晓云.补肾活血方强化骨髓干细胞原位移植治疗急性心肌梗死的研究[D].广州:广州中医药大学,2008.

[15] 雷建国,邹文淑,王剑峰,等.老年单纯收缩期高血压的发病机制及其优化治疗[J].实用医院临床杂志,2011, 8(1): 136-138.

[16] 李迪,黄晓波,张娜,等.成都地区中老年人群单纯收缩期高血压流行特点及其影响因素[J].中华高血压杂志,2015, 23(2):174-177.

[17] Bress AP, Tanner RM, Hess R, et al. Generalizability of SPRINT Results to the U.S. Adult Population. J Am Coll Cardiol. 2016;67(5):463-472.

[18] Ihász F, Karsai I, Kaj M, et al. Characteristics of cardiorespiratory output determining factors among 11-19-year-old boys at rest and during maximal load: Its impact on systolic hypertension. Acta Physiol Hung. 2015;102(3):263-273.

[19] 胡莹.老年单纯收缩期高血压综合干预研究[D].济南:山东中医药大学,2013.

[20] 刘诗.天麻素缓释片治疗老年单纯收缩期高血压的临床试验研究[D].武汉:湖北中医药大学,2013.

[21] Jung Y, Nolta JA. BMI1 Regulation of Self-Renewal and Multipotency in Human Mesenchymal Stem Cells. Curr Stem Cell Res Ther. 2016;11(2):131-140.

[22] Marti LC, Ribeiro AA, Hamerschlak N. Immunomodulatory effect of mesenchymal stem cells. Einstein (Sao Paulo). 2011;9(2):224-228.

[23] Han S, Li YY, Chan BP. Extracellular Protease Inhibition Alters the Phenotype of Chondrogenically Differentiating Human Mesenchymal Stem Cells (MSCs) in 3D Collagen Microspheres. PLoS One. 2016;11(1):e0146928.

[24] Jiang Q, Yu T, Huang K, et al. Remote Ischemic Postconditioning Ameliorates the Mesenchymal Stem Cells Engraftment in Reperfused Myocardium. PLoS One. 2016;11(1):e0146074.

[25] Wang C, Liu Y, Chang C, et al. Human fallopian tube proteome shows high coverage of mesenchymal stem cells associated proteins. Biosci Rep. 2016;36(1): e00297.

[26] Skolekova S, Matuskova M, Bohac M, et al. Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells. Cell Commun Signal. 2016;14:4.

[27] Kucerova L, Skolekova S, Matuskova M, et al. Altered features and increased chemosensitivity of human breast cancer cells mediated by adipose tissue-derived mesenchymal stromal cells. BMC Cancer. 2013;13: 535.

[28] Kamat P, Schweizer R, Kaenel P, et al. Human Adipose-Derived Mesenchymal Stromal Cells May Promote Breast Cancer Progression and Metastatic Spread. Plast Reconstr Surg. 2015;136(1):76-84.

[29] Seo KW, Lee HW, Oh YI, et al. Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model. Cytotherapy. 2011;13(8): 944-955.

[30] Ahn Jo, Lee Hw, Seo Kw, et al. Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma. PLoS One. 2013;8(9):e74897.

[31] 朱希山,台卫平,施薇,等.骨髓间充质干细胞体外诱导向内皮和上皮细胞的分化[J].中国组织工程研究与临床康复, 2011,15(40):7433-7436.